Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States

References

• Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94
   PubMed Web of Science ®Google Scholar
• Runia TF, van Pelt-Gravesteijn ED, Hintzen RQ. Recent gains in clinical multiple sclerosis research. CNS Neurol Disord Drug Targets 2012;11:497-505
   PubMed Web of Science ®Google Scholar
• Campbell JD, Ghushchyan V, McQueen B, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. MS Relat Disord 2014;3:227-36
   PubMed Web of Science ®Google Scholar
• Owens GM, Olvey EL, Skrepnek GH, et al. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm 2013;19(1 Suppl A):S41-S53. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=16103. Accessed July 9, 2015
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al.; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group [No authors listed]. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• O'Connor P, Wolinsky JS, Confavreux C, et al.; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group [No authors listed]. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504; erratum in Lancet 1999:353:678
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group [No authors listed]. PRISMS-4: long term efficacy of interferon-b-1a in relapsing MS. Neurology 2001;56:1628-36; erratum in Neurology 2001;57:1146
   PubMed Web of Science ®Google Scholar
• Biogen Idec Inc. Tecfidera (dimethyl fumarate) delayed-release capsules, for oral use. 2013. http://www.tecfidera.com/pdfs/full-prescribing-information.pdf. Accessed April 16, 2013
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Cost-effectiveness analysis of Tecfidera® in patients with relapsing remitting multiple sclerosis. Version 18.0 technical report. Data on file. Cambridge MA: Biogen, Inc.; 2013
   Google Scholar
• Chilcott J, McCabe C, Tappenden P, et al.; Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003;326:522
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009;12:657-65
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29
   PubMed Web of Science ®Google Scholar
• Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand 1982;65:248-66
   PubMed Web of Science ®Google Scholar
• Brønnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-50
   PubMed Web of Science ®Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med 1997;29:101-6
   PubMedGoogle Scholar
• Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4
   PubMed Web of Science ®Google Scholar
• Sumelahti ML, Tienari PJ, Wikström J, et al. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002;8:350-5
   PubMed Web of Science ®Google Scholar
• Kochanek KD, Xu J, Murphy SL, et al. Deaths: final data for 2009. Natl Vital Stat Rep 2011;60:601-117
   Google Scholar
• Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics (BLS). Consumer price index (CPI) for medical care. 2015. Washington DC. http://www.bls.gov/cpi/cpid1505.pdf. Accessed June 26, 2015
   Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Orme M, Lerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17
   PubMed Web of Science ®Google Scholar
• Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate, and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015;29:71-81
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenberger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012;18(2 Suppl):7-15
   PubMed Web of Science ®Google Scholar
• Morrow TJ. The costs and consequences of multiple sclerosis relapses: a managed care perspective. J Neurol Sci 2007;15(1 Suppl):S39-44
   Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998;4:419-25
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al.; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—1. Value Health 2012;15:796-803
   PubMed Web of Science ®Google Scholar